Previously, AMPK was considered as a potential target in NAFLD treatment [12], by activating downstream target protein PPARwhile inhibiting SREBP-1 through LXR [36,37]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.